Dr.Gregory K. Bell is quoted in this article published by BioPharm International about the regulatory and legal issues associated with bringing recent biosimilars and biobetters to market. Click below to read the article.
Potential MFN impact
Reference country selection HHS provided guidance on setting benchmark pricing by considering the lowest price among a set of reference countries, defined by...